Oncolytics Biotech’s 8-K filed October 14, 2026, discloses that the company expects to receive the final grant payment from the Pancreatic Cancer Action Network before year-end, closing out a $5 million Therapeutic Accelerator Award tied to wind-down enrollment activities in the GOBLET study. That final disbursement arrives because enrollment is finished, not because the trial is: the company now shifts from filling sites to following patients already on study.
GOBLET is a Phase 1/2 gastrointestinal cancer study, and its pancreatic cohort (Cohort 5) completed enrollment earlier in 2026. That cohort is evaluating pelareorep, an oncolytic reovirus, in combination with modified FOLFIRINOX chemotherapy in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma. The grant, established in 2022, was structured to fund exactly this kind of industry-academic push into a disease where chemotherapy combinations remain the backbone of care for most patients.
Pelareorep’s rationale in pancreatic cancer rests partly on biology: the virus preferentially replicates in cells with activated Ras signaling, a mutation present in the large majority of pancreatic ductal adenocarcinomas. Adding an immunogenic oncolytic agent to FOLFIRINOX is a bet that tumor lysis and immune activation together can do something chemotherapy alone has not. Whether that translates in Cohort 5 is what the follow-up data will show, and the final PanCAN payment closes the funding chapter on that question rather than answering it.
The number to watch from here is the Cohort 5 data readout timeline. Enrollment completion is a prerequisite, not an outcome, and the maturation of response and survival data in metastatic pancreatic ductal adenocarcinoma typically takes months after the last patient enrolls. Oncolytics has not disclosed a readout date in this filing, so the final grant receipt marks a financing milestone while the clinical signal remains pending.
Source link: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000072/oncy-20261014.htm
pelareorep: the facts in one place
- Also written: Reolysin, PO-BB0209
- Sponsor: Oncolytics Biotech Inc.
- Mechanism: Oncolytic reovirus that selectively replicates in Ras-activated cancer cells, causing direct tumor lysis and inducing innate and adaptive immune responses; upregulates PD-L1 and increases immune cell infiltration
- Indication studied: First-line metastatic pancreatic ductal adenocarcinoma (PDAC)
- Phase: Phase 1/2
- Enrollment: Approximately 20 patients per arm, two arms, in GOBLET Cohort 5; enrollment complete
- Primary endpoint: Objective response rate and safety, assessed at week 16
- Headline result: All fully enrolled cohorts in the GOBLET study met pre-specified efficacy success criteria
- Registry identifier: not publicly listed
- Current status: GOBLET Cohort 5 enrollment complete; initial results expected first half of 2027; pivotal Phase 3 study design aligned with FDA in November 2025, with launch planned for first half of 2026
- FDA alignment on pivotal Phase 3 study design: November 2025
- Pivotal Phase 3 study launch planned: first half of 2026
- Final PanCAN grant payment expected: Q4 2026
- GOBLET Cohort 5 initial results expected: first half of 2027
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
